Brioche exists because the answer to almost every question a drug development team asks is already in the public record — the regulatory record, the trial registry, the patent ledger, the deal landscape. The work that does not get done is reading it well, in time, and writing it back in a form a CSO, a board, or a reviewer can use.
The bottleneck in drug development is not data. It is memory. The regulatory record knows. The trial registry knows. The patent ledger knows. The cost of not reading that record well is paid every cycle in repeated trials, duplicated submissions, missed precedent, and late competitive surprise.
Brioche reads that record continuously and writes it back as decision-grade analysis. The output is a regulatory pathway, a target validation, a competitive map, a deal precedent — cited to source, dated, and reviewed by a named human before it leaves the practice.
The mission is straightforward. Move the field forward by making the field's own evidence usable, in time, by the teams making the next decision.
Reading the field well, in time, is the precondition for almost every other capability a drug development team wants to build.
Every regulatory action, every comparator approval, every CRL, every label expansion — read into the next decision instead of rediscovered.
The published failure record — discontinued programs, withdrawn submissions, terminated trials — surfaced where it changes the next campaign.
Genetic linkage, biomarker validation, subgroup analyses — assembled into a target-level read, not a search result.
FDA, EMA, PMDA, MHRA, NMPA — and the precedent each one set on the question you are about to ask.
The licensing landscape, the comparator set, the partnership precedent — read from the public deal record, not memory.
Every brief sharpens the next. The methodology improves; the source coverage widens; the reviewer bench grows.
Three currents are moving the field at once — regulatory, technical, economic — and they reinforce. The practice was built for the conditions they create.
The regulatory frameworks for patient-specific therapeutics — expanded access, investigator-initiated INDs, the milasen-class precedent — have matured into a standard pathway, not a one-off. ICH E6 (R3) modernized the conventions for validated computational components in clinical research. FDA guidance for individualized therapies reads as template, not exception. The pathway exists; the bottleneck is the analysis behind the submission.
The orchestration tooling required to run rigorous multi-step analysis at scale — structured workflows, citation pinning, reviewer queues, audit-trail capture — is now production-grade and composable. What used to take a senior analyst three weeks now takes a structured workflow days, at the same evidence standard. Brioche was built around that capability, not retrofitted to it.
Compute and orchestration costs collapsed by an order of magnitude in the same cycle. The marginal cost of a deep optimization loop — reading the full regulatory record on a question, scoring the known therapeutic space against a target, ranking candidate analogs — is now low enough that the engagement economics work even at patient-specific scope. The expensive layer is no longer the compute; it is the discipline.
The platform was built so the same engine reads a regulatory question, a discovery question, and a patient-specific question from one intent abstraction. These three forces, together, make all three economically viable in the same practice.
The reader of a Brioche brief is a CSO, a regulatory affairs lead, a BD partner, or an FDA reviewer. The standard of evidence we hold ourselves to is the standard those readers hold themselves to.
Every claim is cited to a primary source with a retrieval timestamp. Every brief is signed by a named reviewer before delivery. The full audit trail is retained for seven years and provided alongside the deliverable.
The methodology follows ALCOA+ data-integrity principles, version control consistent with 21 CFR Part 11, and a software lifecycle aligned to IEC 62304 Class B medical-device-software conventions.